Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription

Gang Liu, Wenjing Huang, Juan Wang, Xiaohua Liu, Jun Yang, Yu Zhang, Yong Geng, Wenfu Tan, Ao Zhang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A systemic medicinal chemistry campaign was conducted based on a literature hit compound 5 bearing the 4,5-dihydro-2H-benzo[b][1,5]oxazocin-6(3H)-one core through cyclization of two side substituents of the bicyclic skeleton combined with N-atom walking or ring walking and the central ring expansion or extraction approaches, leading to several series of structurally unique tricyclic compounds. Among these, compound 29a was identified as the most potent against the Hedgehog (Hh) signaling pathway showing an IC50 value of 23 nM. Mechanism studies indicated that compound 29a inhibited the Hh signaling pathway by suppressing the expression of the transcriptional factors Gli rather than by interrupting the binding of Gli with DNA. We further observed that 29a was equally potent against both Smo wild type and the two major resistant mutants (Smo D473H and Smo W535L). It potently inhibited the proliferation of medulloblastoma cells and showed significant tumor growth inhibition in the ptch±p53-/- medulloblastoma allograft mice model. Though more studies are needed to clarify the precise interaction pattern of 29a with Gli, its promising in vitro and in vivo properties encourage further profiling as a new-generation Hh signaling inhibitor to treat tumors primarily or secondarily resistant to current Smo inhibitors.

Original languageEnglish (US)
Pages (from-to)8218-8245
Number of pages28
JournalJournal of Medicinal Chemistry
Volume60
Issue number19
DOIs
StatePublished - Oct 12 2017
Externally publishedYes

Fingerprint

Hedgehogs
Medulloblastoma
Walking
Pharmaceutical Chemistry
Cyclization
Skeleton
Inhibitory Concentration 50
Allografts
Neoplasms
Cell Proliferation
DNA
Growth

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription. / Liu, Gang; Huang, Wenjing; Wang, Juan; Liu, Xiaohua; Yang, Jun; Zhang, Yu; Geng, Yong; Tan, Wenfu; Zhang, Ao.

In: Journal of Medicinal Chemistry, Vol. 60, No. 19, 12.10.2017, p. 8218-8245.

Research output: Contribution to journalArticle

Liu, Gang ; Huang, Wenjing ; Wang, Juan ; Liu, Xiaohua ; Yang, Jun ; Zhang, Yu ; Geng, Yong ; Tan, Wenfu ; Zhang, Ao. / Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 19. pp. 8218-8245.
@article{bc9c52a4c86f474788187d2839386fa7,
title = "Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription",
abstract = "A systemic medicinal chemistry campaign was conducted based on a literature hit compound 5 bearing the 4,5-dihydro-2H-benzo[b][1,5]oxazocin-6(3H)-one core through cyclization of two side substituents of the bicyclic skeleton combined with N-atom walking or ring walking and the central ring expansion or extraction approaches, leading to several series of structurally unique tricyclic compounds. Among these, compound 29a was identified as the most potent against the Hedgehog (Hh) signaling pathway showing an IC50 value of 23 nM. Mechanism studies indicated that compound 29a inhibited the Hh signaling pathway by suppressing the expression of the transcriptional factors Gli rather than by interrupting the binding of Gli with DNA. We further observed that 29a was equally potent against both Smo wild type and the two major resistant mutants (Smo D473H and Smo W535L). It potently inhibited the proliferation of medulloblastoma cells and showed significant tumor growth inhibition in the ptch±p53-/- medulloblastoma allograft mice model. Though more studies are needed to clarify the precise interaction pattern of 29a with Gli, its promising in vitro and in vivo properties encourage further profiling as a new-generation Hh signaling inhibitor to treat tumors primarily or secondarily resistant to current Smo inhibitors.",
author = "Gang Liu and Wenjing Huang and Juan Wang and Xiaohua Liu and Jun Yang and Yu Zhang and Yong Geng and Wenfu Tan and Ao Zhang",
year = "2017",
month = "10",
day = "12",
doi = "10.1021/acs.jmedchem.7b01185",
language = "English (US)",
volume = "60",
pages = "8218--8245",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription

AU - Liu, Gang

AU - Huang, Wenjing

AU - Wang, Juan

AU - Liu, Xiaohua

AU - Yang, Jun

AU - Zhang, Yu

AU - Geng, Yong

AU - Tan, Wenfu

AU - Zhang, Ao

PY - 2017/10/12

Y1 - 2017/10/12

N2 - A systemic medicinal chemistry campaign was conducted based on a literature hit compound 5 bearing the 4,5-dihydro-2H-benzo[b][1,5]oxazocin-6(3H)-one core through cyclization of two side substituents of the bicyclic skeleton combined with N-atom walking or ring walking and the central ring expansion or extraction approaches, leading to several series of structurally unique tricyclic compounds. Among these, compound 29a was identified as the most potent against the Hedgehog (Hh) signaling pathway showing an IC50 value of 23 nM. Mechanism studies indicated that compound 29a inhibited the Hh signaling pathway by suppressing the expression of the transcriptional factors Gli rather than by interrupting the binding of Gli with DNA. We further observed that 29a was equally potent against both Smo wild type and the two major resistant mutants (Smo D473H and Smo W535L). It potently inhibited the proliferation of medulloblastoma cells and showed significant tumor growth inhibition in the ptch±p53-/- medulloblastoma allograft mice model. Though more studies are needed to clarify the precise interaction pattern of 29a with Gli, its promising in vitro and in vivo properties encourage further profiling as a new-generation Hh signaling inhibitor to treat tumors primarily or secondarily resistant to current Smo inhibitors.

AB - A systemic medicinal chemistry campaign was conducted based on a literature hit compound 5 bearing the 4,5-dihydro-2H-benzo[b][1,5]oxazocin-6(3H)-one core through cyclization of two side substituents of the bicyclic skeleton combined with N-atom walking or ring walking and the central ring expansion or extraction approaches, leading to several series of structurally unique tricyclic compounds. Among these, compound 29a was identified as the most potent against the Hedgehog (Hh) signaling pathway showing an IC50 value of 23 nM. Mechanism studies indicated that compound 29a inhibited the Hh signaling pathway by suppressing the expression of the transcriptional factors Gli rather than by interrupting the binding of Gli with DNA. We further observed that 29a was equally potent against both Smo wild type and the two major resistant mutants (Smo D473H and Smo W535L). It potently inhibited the proliferation of medulloblastoma cells and showed significant tumor growth inhibition in the ptch±p53-/- medulloblastoma allograft mice model. Though more studies are needed to clarify the precise interaction pattern of 29a with Gli, its promising in vitro and in vivo properties encourage further profiling as a new-generation Hh signaling inhibitor to treat tumors primarily or secondarily resistant to current Smo inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85031285903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031285903&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01185

DO - 10.1021/acs.jmedchem.7b01185

M3 - Article

VL - 60

SP - 8218

EP - 8245

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -